The Salk approach, tested in a mouse model, points to cheaper and more effective treatments for humans
For most people with hemophilia B, whose bodies can’t properly form blood clots, constant injections to replenish their clotting factors are a way of life. But now, Salk researchers have demonstrated in mice that hemophilia B can be treated for life with one single injection containing disease-free liver cells that can produce their missing clotting factor. The finding, published in the journal Cell Reports on May 1, 2018, could drastically change what it means to be diagnosed with hemophilia B, and could pave the way toward similar treatments for other, related genetic disorders.
Hemophilia B is caused by defects in the gene for a protein called clotting factor IX (FIX). Hemophiliacs may make reduced amounts of the protein, or lack a functional version altogether, leading to life-threatening delays in blood clotting. Currently, patients are treated with injections—as often as a few times a week—containing FIX made in animal cells and then purified. But the approach is expensive, time-consuming and can become less effective over time.
Recently, Salk scientists developed a new approach, treating mice genetically engineered to have hemophilia B with strands of messenger RNA encoding the FIX gene. Like the standard treatment, however, this required repeat injections each time levels of the messenger RNA ran low. So the scientists wanted to try a more permanent approach: transplanting healthy liver cells, capable of producing FIX, into patients.
“The appeal of a cell-based approach is that you minimize the number of treatments that a patient needs,” says Suvasini Ramaswamy, a former Salk research associate in the Verma lab and first author of the new paper. “Rather than constant injections, you can do this in one shot.”
Since donor livers are often in short-supply, the researchers instead turned to stem-cell strategies to produce the healthy liver cells. They collected blood samples from two human patients with severe hemophilia B, who are unable to produce FIX. Then, in the lab, they reprogrammed the cells into induced pluripotent stem cells (iPSCs), which have the capability to turn into many other cell types, including liver. Using CRISPR/Cas9, a tool that can alter genes, they then repaired the mutations in each patient’s FIX gene. Finally, they coaxed those repaired cells to develop into liver precursor cells called hepatocyte-like cells (HLCs) and transplanted them into mice with hemophilia B.
Rather than perform surgery on hemophilic mice—a risky undertaking when their blood can’t always clot—the team transplanted the HLCs through the spleen to distribute the cells uniformly in the liver.
Not only did the new HLCs produce FIX, but they produced enough of the protein to allow the mice to form normal blood clots, and the cells continued to survive—and produce FIX—for at least a year after the transplantation.
In people with hemophilia, using their own cells to generate healthy HLCs, then transplanting them back into their bodies, could help avoid the immune complications that often accompany cell therapies. But more work is needed to translate the findings to the clinic.
“A lot of things have to happen before this can go into humans,” says Ramaswamy.
Already, she adds, the work demonstrates the value in combining stem-cell reprogramming and new gene-modifying approaches to treat genetic diseases.
The Latest on: Hemophilia B
via Google News
The Latest on: Hemophilia B
- EuroBiotech Report—AstraZeneca clear-out, uniQure data, Grey Wolf, Pathios and CureVac on February 14, 2019 at 8:03 am
Elsewhere, uniQure's revised hemophilia B gene therapy cleared another clinical hurdle, adding to the impression that it can compete with Pfizer and Spark Therapeutics. In the U.K., Grey Wolf Therapeu... […]
- Hemophilia of Georgia Names Edith A. Rosato Chief Executive Officer on February 14, 2019 at 5:31 am
Hemophilia of Georgia (www.hog.org ... (Full bio on request.) Media Contact: B. Andrew (Drew) Plant [email protected] 678-637-5532 […]
- Uniqure gene therapy still looking good in hemophilia B at second interim peek on February 8, 2019 at 3:03 pm
DUBLIN – The mood music coming out of Uniqure NV's phase IIb trial for its hemophilia B gene therapy, AMT-061, remains positive. A second interim readout last week, after an initial peek at the data s... […]
- UniQure gene therapy shows promising result in mid-stage trial on February 8, 2019 at 9:42 am
(Reuters) – Gene therapy company UniQure NV said on Friday its treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study. Com... […]
- This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why on February 8, 2019 at 9:41 am
Gene therapy player Uniqure (QURE) could garner takeover interest, an analyst said Friday after the biotech unveiled promising data in hemophilia B treatment. Uniqure tested its gene therapy in three ... […]
- Gene therapy increases factor IX activity in severe hemophilia B on February 8, 2019 at 8:11 am
The investigational gene therapy AMT-061 showed increases in factor IX activity sustained at 25% to 51% of normal among patients with severe or moderately severe hemophilia B, according to updated cli... […]
- UniQure’s hemophilia B gene therapy clears another clinical test on February 8, 2019 at 6:02 am
UniQure has posted 12-week data on its hemophilia B gene therapy. The update suggests FIX activity increases seen at six weeks are sustainable, giving uniQure a boost as it races Spark Therapeutics to ... […]
- Enrollment in the Phase 2 portion of the trial is complete on February 8, 2019 at 5:03 am
“The positive data from our clinical trial demonstrate clinical proof-of-concept for MarzAA as a subcutaneous treatment option for individuals with hemophilia A or B with inhibitors,” said Dr ... […]
- UniQure's gene therapy for hemophilia B continues to show treatment effect in mid-stage study; shares up 2% premarket on February 8, 2019 at 4:36 am
UniQure (NASDAQ:QURE) is up 2% premarket on light volume following its announcement of updated results from its open-label single-arm Phase 2b clinical trial evaluating gene therapy AMT-061 in ... […]
via Bing News